COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03716180
Recruitment Status : Active, not recruiting
First Posted : October 23, 2018
Last Update Posted : June 1, 2020
Susan G. Komen Breast Cancer Foundation
Breast Cancer Research Foundation
Terri Brodeur Breast Cancer Foundation
Information provided by (Responsible Party):
Adrienne G. Waks, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : January 1, 2021
Estimated Study Completion Date : September 1, 2030